A large proportion of acute myeloid leukemia (AML) patients are treated by non-specialist community oncologists, who may not have the time or energy to attend conferences or lectures presenting specialized AML research. We interviewed Naval Daver, MD, of MD Anderson Cancer Center, Houston, TX, at the 23rd Congress of the European Hematological Association (EHA) 2018 in Stockholm, Sweden about the importance of creating new, easy-access platforms for AML education, such as VJHemOnc. He discusses the benefits of such platforms, along with a few of the dangers that may be accompanied by poor knowledge of the newest AML treatments and research.
The importance of AML education amongst practitioners
